PDE5 inhibitors, such as sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra or Staxyn), and avanafil (Stendra), are primarily used to treat erectile dysfunction by improving blood flow to ...
To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...
Please provide your email address to receive an email when new articles are posted on . Patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 ...
There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...
Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Let’s cut to the chase: erectile dysfunction (ED) ...
(HealthDay News) — Use of phosphodiesterase type 5 (PDE5) inhibitors does not appear to increase the risk of melanoma, according to the conclusions of a meta-analysis published online in the Journal ...
Treatment with sildenafil or tadalafil was not associated with a reduced risk for incident Alzheimer’s disease and related dementia in patients with pulmonary hypertension, according to a study ...
SEONGNAM, South Korea--(BUSINESS WIRE)--A recently published research article in Nature Aging by a Cleveland Clinic Genomic Medicine Institute (GMI) research team, led by Feixiong Cheng, Ph.D., ...
Daily use of the phosphodiesterase type 5 (PDE5) inhibitor tadalafil (Cialis) significantly reduced symptoms caused by chronic prostatitis, also known as chronic pelvic pain syndrome (CP/CPPS), in a ...
Use of a phosphodiesterase type-5 (PDE5) inhibitor was associated with a lower risk for death and cardiovascular events than alprostadil for the treatment of erectile dysfunction in men with stable ...
LONDON--(BUSINESS WIRE)--The global phosphodiesterase (PDE) inhibitors market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback